lapatinib / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

94 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lapatinib / Generic mfg.
CHERLOB, NCT00429299: Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer

Checkmark ESMO 2014
Sep 2014 - Sep 2014: ESMO 2014
Checkmark P2 data - ESMO 2012
Sep 2012 - Sep 2012: P2 data - ESMO 2012
Checkmark P2 data
More
Completed
2b
121
Europe
lapatinib, Tyverb/Tykerb, trastuzumab, Herceptin, paclitaxel, Taxol, fluorouracil, epidoxorubicin, cyclophosphamide
GlaxoSmithKline
Neoplasms, Breast
06/12
06/12
NCT00044343: GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin

Completed
2
80
US, Canada
lapatinib
GlaxoSmithKline
Colorectal Cancer
10/03
10/03
NCT00062686: GW572016 For Treatment Of Refractory Metastatic Breast Cancer

Completed
2
200
Europe, RoW
GW572016
GlaxoSmithKline
Neoplasms, Breast
02/05
02/05
NCT00051103: Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.

Completed
2
US
Investigational Cancer Drug
GlaxoSmithKline
Metastatic Breast Cancer, Neoplasms, Breast
06/05
06/05
NCT00044330: GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin

Completed
2
80
US
GW572016
GlaxoSmithKline
Metastatic Breast Cancer
06/05
06/05
NCT00111787 / 2004-001905-93: Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer

Completed
2
49
US, Canada, Europe, RoW
Lapatinib, Paclitaxel
GlaxoSmithKline
Neoplasms, Breast
11/06
11/06
NCT00462956: GW572016 In Patients With Advanced Or Metastatic Breast Cancer

Completed
2
59
Japan, RoW
Tykerb
GlaxoSmithKline
Neoplasms, Breast
12/06
12/06
NCT00259987: Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus

Completed
2
24
US, Europe, RoW
Lapatinib (GW572016) oral tablets
GlaxoSmithKline
Adenocarcinoma
 
05/07
NCT00105950 / 2004-001906-29: Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer

Completed
2
126
US, Canada, Europe, RoW
lapatinib
GlaxoSmithKline
Neoplasms, Breast
09/07
05/10
NCT00263588 / 2005-003944-68: Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer

Completed
2
242
Europe, Canada, Japan, US, RoW
lapatinib
Novartis Pharmaceuticals
Neoplasms, Breast
09/07
03/18
NCT00371566 / 2005-002485-11: A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer

Completed
2
107
Europe, RoW
Lapatinib oral tablets, platinum - based chemotherapy, radiotherapy, Placebo
GlaxoSmithKline
Squamous Cell Carcinoma of Head and Neck
12/07
12/07
NCT00089999: Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer

Completed
2
138
US, Europe, RoW
Lapatinib
GlaxoSmithKline
Neoplasms, Breast
03/08
03/08
NCT00356811 / 2005-003945-16: Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

Completed
2
57
Europe, RoW
Lapatinib oral tablets, Tykerb/ Tyverb, Paclitaxel infusion, Taxol
GlaxoSmithKline
Neoplasms, Breast
03/08
12/13
NCT00073008: A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer

Terminated
2
131
US, Canada
GW572016 (lapatinib)
GlaxoSmithKline
Lung Cancer, Non-Small Cell
07/08
07/08
NCT00430781 / 2006-000236-27: Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

Completed
2
228
US, Canada, Europe, RoW
pazopanib (GW786034), lapatinib (GW572016)
GlaxoSmithKline
Neoplasms, Uterine Cervix, Metastatic Cervical Cancer
07/08
07/11
NCT00444535: Lapatinib and Bevacizumab for Metastatic Breast Cancer

Completed
2
52
US
lapatinib, Tykerb/Tyverb, bevacizumab
Novartis Pharmaceuticals
Neoplasms, Breast
07/08
06/20
NCT00347919 / 2005-004350-28: Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

Checkmark +lapatinib (Breast)
Jan 2013 - Jan 2013: +lapatinib (Breast)
Checkmark Data
Feb 2011 - Feb 2011: Data
Completed
2
189
US, Canada, Europe, RoW
pazopanib (GW786034) 400 mg, lapatinib (GW572016) 1500 mg, lapatinib (GW572016) 1000 mg, pazopanib (GW786034) 800 mg
GlaxoSmithKline
Neoplasms, Breast
08/08
03/15
NCT00437073: Brain Metastases In ErbB2-Positive Breast Cancer

Terminated
2
22
US, Canada, Europe, RoW
capecitabine, Xeloda, topotecan, Hycamtin, lapatinib, Tykerb/Tyverb
GlaxoSmithKline
Neoplasms, Breast
01/09
02/10
NCT00320411: GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer

Completed
2
62
Japan, RoW
lapatinib
GlaxoSmithKline
Neoplasms, Breast
04/09
04/09
TOPO-LAPA, NCT00888810 / 2007-005706-44: Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer

Terminated
2
39
Europe
TOPOTECAN, HYCAMTIN, LAPATINIB, TYVERB
Centre Francois Baclesse, GlaxoSmithKline, Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Cancer, Ovarian, Relapse, Chemotherapy
 
 
NCT00447226: Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

Terminated
2
32
US
Oral lapatinib tablets or placebo tablets
GlaxoSmithKline
Cancer
05/09
09/09
NCT00528281 / 2007-002472-34: A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase

Completed
2
18
Europe
Lapatinib, Pemetrexed
GlaxoSmithKline
Lung Cancer, Non-Small Cell
05/09
05/09
NCT00387127 / 2005-003767-23: Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer

Checkmark + chemoradiotherapy (HNC)
Dec 2012 - Dec 2012: + chemoradiotherapy (HNC)
Completed
2
67
US, Canada, Europe, RoW
Lapatinib oral tablets, radiotherapy, cisplatin chemotherapy
GlaxoSmithKline
Neoplasms, Head and Neck
06/09
01/14
NCT00574171: Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma

Completed
2
29
US
lapatinib, Tykerb, Capecitabine, Xeloda
University of Wisconsin, Madison, GlaxoSmithKline
Metastatic Colorectal Cancer
08/09
08/09
NCT00479856: Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

Terminated
2
9
US
Lapatinib, Capecitabine, Docetaxel, nab-Paclitaxel
GlaxoSmithKline
Relapsed Breast Cancer, Neoplasms, Breast
09/09
03/10
APRiCOT-B, NCT00657137: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)

Terminated
2
12
US
apricoxib + lapatinib + capecitabine, placebo + lapatinib + capecitabine
Tragara Pharmaceuticals, Inc.
Breast Cancer
09/09
09/09
VEG102857, NCT00350727 / 2006-001278-26: Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma

Checkmark P1/2 data in relapsed malignant glioma
Feb 2013 - Feb 2013: P1/2 data in relapsed malignant glioma
Completed
2
75
US, RoW
pazopanib, lapatinib
GlaxoSmithKline
Glioma
12/09
12/09
LPT109096, NCT00524303: Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

Checkmark Lapatinib +/- trastuzumab in addition to standard neoadjuvant breast cancer therapy
Dec 2013 - Dec 2013: Lapatinib +/- trastuzumab in addition to standard neoadjuvant breast cancer therapy
Completed
2
100
US
Trastuzumab, Paclitaxel, FEC75, Lapatinib
GlaxoSmithKline
Neoplasms, Breast
10/10
08/15
NCT00404066: Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer

Completed
2
21
US
Lapatinib, GW572016, Doxorubicin, Adriamycin, Adriablastin, Cyclophosphamide, Cytoxan, ASTA, Docetaxel, Taxotere, Pegfilgrastim, Neulasta, Filgrastim, Neupogen, Granulocyte Colony-Stimulating Factor (G-CSF), Dexamethasone, Adexone, Trastuzumab, Herceptin
George Albert Fisher, GlaxoSmithKline, Sanofi
Breast Cancer, Metastatic Breast Cancer
12/10
03/11
NCT00477464: Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer

Completed
2
51
Japan
Lapatinib, capecitabine
GlaxoSmithKline
Metastatic Breast Cancer, Neoplasms, Breast
12/10
12/10
GLICO-0801, NCT01050322: Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.

Checkmark SABCS 2013
Jan 2014 - Jan 2014: SABCS 2013
Completed
2
142
RoW
Lapatinib Vinorelbine, Lapatinib Capecitabine, Gemcitabine Lapatinib
Latin American Cooperative Oncology Group, GlaxoSmithKline
BRMS1, Performance Status Zero to Two for Beginning the Study, Patient With a Maximum of One Chemotherapy, Patient With Progression After Taxanes
12/10
09/11
NCT01068704 / 2009-016622-13: Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

Completed
2
4
US, RoW
BMS-690514, Lapatinib, Letrozole
Bristol-Myers Squibb
Breast Cancer
12/10
12/10
ELATE, NCT01205217: Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer

Withdrawn
2
0
Europe
Lapatinib, Trastuzumab, Epirubicin, Cyclophosphamide, Paclitaxel
GlaxoSmithKline
Neoplasms, Breast
12/10
12/10
TBCRC 006, NCT00548184: Lapatinib and Trastuzumab With or Without Endocrine Therapy

Checkmark
Apr 2013 - Apr 2013: 
Completed
2
65
US
Lapatinib, TyKerb, Trastuzumab, Herceptin, Endocrine, Varies
Baylor Breast Care Center, GlaxoSmithKline
Breast Cancer
01/11
01/14
NCT00709761: Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC

Checkmark P2 data
Dec 2012 - Dec 2012: P2 data
Checkmark P2 data-SABCS
Dec 2011 - Dec 2011: P2 data-SABCS
Completed
2
60
US
Lapatinib/nab-Paclitaxel
Novartis Pharmaceuticals
Neoplasms, Breast
01/11
01/18
NCT00777101: Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Checkmark Neratinib vs. lapatinib+capecitabine in pts with HER2+ adv BC
Aug 2013 - Aug 2013: Neratinib vs. lapatinib+capecitabine in pts with HER2+ adv BC
Checkmark P2 data - SABCS
Dec 2011 - Dec 2011: P2 data - SABCS
Completed
2
233
Canada, Japan, US, Europe, RoW
Neratinib, HKI-272, Lapatinib, Tykerb, Tyverb, Capecitabine, Xeloda
Puma Biotechnology, Inc.
Advanced Breast Cancer, Breast Cancer
03/11
06/18
LETLOB, NCT00422903 / 2006-001907-13: Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
2
92
Europe
lapatinib, letrozole, placebo
GlaxoSmithKline
Neoplasms, Breast
04/11
04/11
NCT00526669: Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib

Completed
2
68
US, Canada, RoW
Lapatinib and Capecitabine
GlaxoSmithKline
Neoplasms, Gastrointestinal Tract
04/11
01/15
NCT00206427: Neoadjuvant GW572016 to Treat Breast Cancer

Completed
2
49
US
GW572016, TyKerb, Lapatinib, lapatinib
Baylor Breast Care Center, GlaxoSmithKline
Breast Cancer
06/11
02/12
NCT00482391: Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Checkmark ASCO-BC 2013
Sep 2013 - Sep 2013: ASCO-BC 2013
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
2
95
US
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, laboratory biomarker analysis
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Dana-Farber Cancer Institute, GlaxoSmithKline
Breast Cancer
07/11
07/11
NCT00820924: Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Terminated
2
23
Europe
LAPATINIB
GlaxoSmithKline
Neoplasms, Breast
07/11
07/11
MAPLE, NCT00299286: Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer

Checkmark P2 data: SABCS 2012
Dec 2012 - Dec 2012: P2 data: SABCS 2012
Completed
2
121
Europe
Lapatinib, Tyverb, Lapatinib-Placebo
Institute of Cancer Research, United Kingdom, GlaxoSmithKline
Breast Cancer
08/11
08/11
NCT00826267: 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

Checkmark P2 data - ASCO
Jun 2012 - Jun 2012: P2 data - ASCO
Completed
2
29
US, RoW
lapatinib, BIBW 2992, trastuzumab
Boehringer Ingelheim
Breast Neoplasms
08/11
 
NCT00841828 / 2007-007031-13: Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Checkmark In HER2+ve BC pts
Jan 2014 - Jan 2014: In HER2+ve BC pts
Checkmark P2 data-SABCS
Dec 2011 - Dec 2011: P2 data-SABCS
Completed
2
102
Europe
Epirubicin, Ellence, Pharmorubicin, Cyclophosphamide, Cytoxan, Neosar, Endoxan, Docetaxel, Taxotere, Lapatinib, Tykerb, Trastuzumab, Herceptin
Spanish Breast Cancer Research Group, GlaxoSmithKline
Breast Cancer
12/11
12/13
GERICO09, NCT01262469 / 2009-015981-73: Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer.

Completed
2
4
Europe
lapatinib + capecitabine, Tyverb, Xeloda
UNICANCER, GlaxoSmithKline
Metastatic Breast Cancer, 70 Years Old Patients and Over, After One Line of Chemotherapy With Trastuzumab
12/11
11/13
NCT01128543: Lapatinib in Combination With Vinorelbine

Completed
2
29
RoW
lapatinib and Vinorelbine
GlaxoSmithKline
Cancer
03/12
03/12
NCT00709618: Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Terminated
2
44
US
Lapatinib, Vinorelbine, Lapatinib, Vinorelbine
GlaxoSmithKline
Neoplasms, Breast
05/12
05/12
NCT00903656 / 2008-004530-25: Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy

Terminated
2
24
Europe
doxorubicinhydrochloride, Lapatinib
Arbeitsgemeinschaft medikamentoese Tumortherapie, GlaxoSmithKline
Metastatic Breast Cancer
05/12
05/12
VITAL, NCT01013740: Lapatinib in Combination With Vinorelbine

Checkmark In combination with vinorelbine in women with ErbB2+ve mBC
Jan 2014 - Jan 2014: In combination with vinorelbine in women with ErbB2+ve mBC
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P2 trial design-SABCS
More
Completed
2
112
Europe, RoW
Vinorelbine, Lapatinib, Capecitabine
Novartis Pharmaceuticals
Cancer
08/12
03/16
NCT00973739: Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Checkmark P2 data
Jul 2012 - Jul 2012: P2 data
Completed
2
21
US
Lapatinib, Tykerb
NYU Langone Health, GlaxoSmithKline
Neurofibromatosis 2, Vestibular Schwannoma
10/12
11/12
NCT00881621: Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

Checkmark Data ASCO
Jun 2012 - Jun 2012: Data ASCO
Terminated
2
17
US
Lapatinib and Capecitabine, Tykerb, GW572016
Georgetown University, GlaxoSmithKline
Pancreas Cancer
12/12
06/13
NCT00490061: Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy

Terminated
2
17
US
Lapatinib, Tykerb/Tyverb, GlaxoSmithKline, Radiotherapy (radiation), IMRT - Intensity Modulated Radiotherapy, G.E. Healthcare 1.5T MR, systems revision 12.0 M5, G.E. Healthcare MRI Device and Software, DCE-MRI, Dynamic contrast-enhanced magnetic resonance imaging
Quynh-Thu Le, GlaxoSmithKline
Head and Neck Cancer, Carcinoma, Squamous Cell, Head and Neck Cancers
01/13
06/16
NCT01382706: Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

Terminated
2
15
US
docetaxel, RP 56976, Taxotere, TXT, lapatinib ditosylate, GSK572016, GW-572016, GW2016, Lapatinib, Tykerb, immunohistochemistry staining method, immunohistochemistry, fluorescence in situ hybridization, fluorescence in situ hybridization (FISH), laboratory biomarker analysis
University of Southern California, National Cancer Institute (NCI), GlaxoSmithKline
Recurrent Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
07/13
12/17
NCT00756470: Phase II Neoadjuvant in Inflammatory Breast Cancer

Terminated
2
15
US
Lapatinib, Tykerb, GW572016, Paclitaxel, Taxol, 5-Fluorouracil (5-FU), 5-FU, Adrucil, Efudex, Epirubicin, Cyclophosphamide, Cytoxan, Neosar
M.D. Anderson Cancer Center, GlaxoSmithKline
Breast Cancer
10/13
10/13
NCT00470704: Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark P2 data-SABCS
Dec 2011 - Dec 2011: P2 data-SABCS
Active, not recruiting
2
87
US
Lapatinib, Tykerb, Herceptin, trastuzumab
Nancy Lin, MD, GlaxoSmithKline, Novartis
Breast Cancer
11/13
12/24
NCT01138046: Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC

Completed
2
12
Japan
Lapatinib in combination with weekly paclitaxel
GlaxoSmithKline
Neoplasms, Breast
01/14
01/14
NCT01441596 / 2010-021415-16: Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Checkmark SABCS 2014
Dec 2014 - Dec 2014: SABCS 2014
Checkmark P2 data - ASCO
Jun 2012 - Jun 2012: P2 data - ASCO
Completed
2
121
US, Canada, Europe, RoW
Vinorelbine, Investigator's choice of treatment, afatinib
Boehringer Ingelheim
Breast Neoplasms, Neoplasm Metastasis
02/14
08/14
NCT01769508: Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

Terminated
2
12
US
5-Fluorouracil, Combined Modality Treatment, Oxaliplatin, Lapatinib, Radiation Therapy
SCRI Development Innovations, LLC, GlaxoSmithKline
HER2 Positive Esophagogastric Cancer
02/14
02/15
2013-001203-36: Clinical trial to assess wether Lapatinib in association with Capecitabine and Radiation performs better than Capecitabine and Radiation in patients with localized rectal cancer Ensaio clínico para avaliar se a associação de Lapatinib com Capecitabina e Radioterapia é melhor do que Capecitabina e Radioterapia em doentes com cancro do recto localizado

Ongoing
2
80
Europe
Film-coated tablet, Tyverb
Instituto Português de Oncologia do Porto Francisco Gentil, EPE, GlaxoSmithKline, IPO Porto FG, EPE
Rectal cancer stage II Rectal cancer stage III Cancro do Reto, estádio II Cancro do Reto, estádio III, Rectal Cancer Cancro do Reto, Diseases [C] - Cancer [C04]
 
 
HELEX, NCT00999804: Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Active, not recruiting
2
128
US
Lapatinib, TyKerb, Letrozole, Femara, Trastuzumab, Herceptin
Baylor Breast Care Center, Translational Breast Cancer Research Consortium, GlaxoSmithKline
Breast Cancer
11/14
01/24
NCT01499160: Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

Checkmark P2 data (SABCS 2012)
Dec 2012 - Dec 2012: P2 data (SABCS 2012)
Terminated
2
7
US
letrozole, Femara, lapatinib, Tykerb, everolimus, Afinitor
University of Maryland, Baltimore, Novartis Pharmaceuticals, GlaxoSmithKline
Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis
11/14
12/16
NCT01985893: Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer

Withdrawn
2
0
Europe
Lapatinib plus trastuzumab, Tyverb plus Herceptin
Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V., OnkoDataMed GmbH
Metastatic Breast Cancer
03/15
03/15
NCT02668939: Presurgical Treatment With Single-Agent Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by Six Cycles of Docetaxel & Carboplatin With Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib in Patients With HER2/+ Operable Breast Cancer

Active, not recruiting
2
140
US
TCH, Trastuzumab, Docetaxel, carboplatin, TCTy, Lapatinib, docetaxel, TCHTy, lapatinib
Translational Oncology Research International, Sanofi, GlaxoSmithKline
Adenocarcinoma of the Breast, Tumor HER2/Neu Positive
01/16
 
NCT01934894: Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

Terminated
2
11
US
cabazitaxel, Jevtana, XRP6258, lapatinib, Tykerb, GW572016
SCRI Development Innovations, LLC, Novartis, GlaxoSmithKline, Sanofi
Metastatic Breast Cancer With Intracranial Metastases
02/16
04/17
2009-009885-15: A study to determine the safety and efficacy of Laptinib in combination with Vinorelbine or Capecitabine in Women with ErbB2‑Overexpressing Metastatic Breast Cancer.

Completed
2
105
Europe, RoW
Lapatinib, Vinorelbine, Capecitabine, GW572016, Film-coated tablet, Concentrate for solution for infusion, Tyverb, Navelbine, Xeloda
GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline SA, GlaxoSmithKline Research & Development Ltd, , GSK R&D
Breast Cancer (with ErbB2 Overexpressing Metastatic Breast Cancer), Metastatic Breast Cancer, Diseases [C] - Cancer [C04]
 
 
NCT01283789: Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

Unknown status
2
23
US
Lapatinib and RAD-001, everolimus, tykerb
University of Kansas Medical Center, Novartis, GlaxoSmithKline
Metastatic Breast Cancer
04/16
04/17
PAMELA, NCT01973660 / 2013-001036-22: PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer

Completed
2
151
Europe
Lapatinib, Tyverb, Tykerb, Trastuzumab, Herceptin, Herclon, Endocrine Therapy, Letrozol, Letrozole, Devazol, Femara, Galdar, Loxifan, Tamoxifen, Tamoxifeno, Nolvadex, Istubal, Valodex, Paclitaxel, Abraxane, Taxol
SOLTI Breast Cancer Research Group, Novartis
Breast Cancer
06/16
12/17
NCT00721630: Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer

Completed
2
24
US
capecitabine, lapatinib
Memorial Sloan Kettering Cancer Center, GlaxoSmithKline
Breast Cancer
07/16
07/16
NCT01612351: Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Active, not recruiting
2
40
US
Carboplatin, Paraplatin, Paclitaxel, Taxol, Lapatinib, Tykerb, Cisplatin, Platinol, Ipsilateral Radiation, Radiation therapy, Bilateral Radiation, Transoral Surgery, Surgery
UNC Lineberger Comprehensive Cancer Center, GlaxoSmithKline
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
11/16
11/31
NCT01891357 / 2012-003679-21: Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

Terminated
2
64
Europe
Biopsy before and after three weeks of study treatment, paclitaxel, lapatinib, trastuzumab
West German Study Group, GlaxoSmithKline
Carcinoma, Ductal, Breast
11/16
11/16
NCT01137994: A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer

Withdrawn
2
0
US
Lapatinib, Trastuzumab, Docetaxel, Paclitaxel, Vinorelbine
GlaxoSmithKline
Neoplasms, Breast
12/16
03/18
NCT01700010: Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer

Withdrawn
2
0
US
Lapatinib and Paclitaxel
University of Michigan Rogel Cancer Center, GlaxoSmithKline
Urothelial Cancer, Bladder Cancer
01/17
01/19
GIM12-TYPHER, NCT02238509 / 2013-005044-29: Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies

Unknown status
2
154
Europe
Lapatinib, Tyverb, Trastuzumab, Herceptin
Consorzio Oncotech, Clinical Research Technology S.r.l.
Metastatic Breast Cancer
10/17
10/17
NCT02294786: Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Terminated
2
62
Europe, RoW
Lapatinib, Capecitabine, Octreotide
Novartis Pharmaceuticals
Cancer
10/17
10/17
NCT01273610 / 2004-002614-10: Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

Active, not recruiting
2
40
US
Lapatinib, Tykerb, Tyverb, GSK572016, GW-572016, GW2016, Trastuzumab, Herceptin, laboratory biomarker analysis, Correlative studies, pharmacological study
City of Hope Medical Center, GlaxoSmithKline, Novartis
Breast Neoplasms, HER2/Neu Positive, Geriatric Health Services
02/18
02/25
ELTOP, UMIN000005219: Japanese A Randomized Phase II Study Comparing Trastuzumab + Capecitabine Combination (HX Therapy) Versus Lapatinib + Capecitabine Combination (LX Therapy) in HER2-Positive Metastatic or Unresectable Locally Advanced Breast Cancer Previously Treated with

Completed
2
110
Japan
Herceptin (trastuzumab) - Roche, capecitabine - Generic mfg., lapatinib - Generic mfg.
GlaxoSmithKline K.K.
HER2-positive metastatic or unresectable locally advanced breast cancer
 
 
NCT01827163: Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
20
US
Paclitaxel, Trastuzumab, Lapatinib, Pegfilgrastim
Memorial Sloan Kettering Cancer Center, GlaxoSmithKline
HER2-Positive Early Stage Breast Cancer
01/19
01/19
TEAL, NCT02073487: Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

Completed
2
32
US
T-DM1, trastuzumab emtansine, Kadcyla, Trastuzumab, Herceptin, Lapatinib, tykerb, Abraxane, nab-paclitaxel, Paclitaxel, Taxol, Pertuzumab, Perjeta
The Methodist Hospital Research Institute, Celgene Corporation, Novartis
Breast Cancer
01/19
01/19
NCT02213042 / 2014-001220-30: Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

Terminated
2
42
Europe, US, RoW
Lapatinib, Trastuzumab, Aromatase Inhibitors (AIs)
Novartis Pharmaceuticals
Neoplasms, Breast
06/20
06/20
TRYHARD, NCT01711658: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.

Completed
2
142
Canada, US
IMRT, Cisplatin, placebo, Lapatinib
Radiation Therapy Oncology Group, GlaxoSmithKline, Novartis
Non-HPV Locally Advanced Head and Neck Cancer
12/20
09/22
NCT01591577: Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme

Completed
2
50
US
Lapatinib/Temozolomide/radiation
Jonsson Comprehensive Cancer Center, GlaxoSmithKline, Novartis
Newly Diagnosed Glioblastoma Multiforme
05/24
05/24
NCT00536809: Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer

Completed
1/2
12
US
lapatinib, oxaliplatin, capecitabine
GlaxoSmithKline
Neoplasms, Colorectal
10/08
10/08
NCT00316407: Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients

Completed
1/2
30
US
lapatinib (GW572016), Tykerb, Carboplatin, Paraplatin, Paclitaxel, Taxol
Swedish Medical Center, GlaxoSmithKline
Ovarian Epithelial Cancer Stage III, Stage IV Ovarian Cancer, Stage IV Breast Cancer
11/09
11/09
NCT00251433 / 2005-000846-35: GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

Checkmark In combination with docetaxel+trastuzumab in 1st-line treatment of HER2+ve mBC
Jul 2013 - Jul 2013: In combination with docetaxel+trastuzumab in 1st-line treatment of HER2+ve mBC
Terminated
1/2
53
Europe, US
lapatinib, docetaxel, trastuzumab, GW572016
Novartis Pharmaceuticals
Neoplasms, Breast
06/10
06/22
NCT00952692: Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer

Completed
1/2
12
US
dHER2 + AS15 ASCI, dHER2 ASCI, dHER2 + AS15, Lapatinib, Tykerb
Michael Morse, MD, GlaxoSmithKline
Metastatic Breast Cancer
07/11
04/12
LapDoc, NCT01044485: Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
1/2
17
Europe
lapatinib, docetaxel
Centre Georges Francois Leclerc, GlaxoSmithKline, Sanofi
Metastatic Breast Cancer
11/11
 
NCT00953576: Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer

Terminated
1/2
11
US
ketoconazole, Nizoral, hydrocortisone, Cortef, Hydrocortone, dutasteride, Avodart, lapatinib, lapatinib ditosylate, Tyverb
Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Massachusetts General Hospital, Prostate Cancer Foundation Clinical Research Consortium, GlaxoSmithKline
Prostate Cancer
04/13
04/13
NCT00450892 / 2006-000864-94: Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer

Checkmark ESMO 2014
Sep 2014 - Sep 2014: ESMO 2014
Completed
1/2
129
Europe
docetaxel+lapatinib, docetaxel + trastuzumab, docetaxel + trastuzumab + lapatinib
European Organisation for Research and Treatment of Cancer - EORTC, GlaxoSmithKline
Breast Cancer
07/13
07/13
NCT01138384: Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P1/2 data
Nov 2012 - Nov 2012: P1/2 data
Completed
1/2
19
Canada
Foretinib, Lapatinib
NCIC Clinical Trials Group, GlaxoSmithKline
Breast Cancer
05/14
02/15
2014-002209-39: Phase I/II study with lapatinib plus trametinib in patients with metastatic non-small cell lung cancer with a mutation in the KRAS gene Fase I/II studie met de combinatie van lapatinib met trametinib bij patiënten met uitgezaaid niet kleincellig longkanker met een KRAS genmutatie

Ongoing
1/2
132
Europe
Lapatinib, trametinib, docetaxel, Tablet, Film-coated tablet, Concentrate and solvent for concentrate for solution for infusion, Mekinist
The Netherlands Cancer Institute, Novartis
non-small cell lung cancer niet-kleincellig longkanker, lung cancer longkanker, Diseases [C] - Cancer [C04]
 
 
NCT00912275: Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer

Completed
1/2
46
RoW
lapatinib plus oral vinorelbine, Tykerb, Navelbine
National Taiwan University Hospital, GlaxoSmithKline
Metastatic Breast Cancer
03/15
07/17
NCT01479179: Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

Withdrawn
1/2
0
US
AMG 479, Trastuzumab, Herceptin
M.D. Anderson Cancer Center, Amgen
Breast Cancer
11/15
 
NCT02422199: A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

Unknown status
1/2
128
RoW
pyrotinib, Lapatinib, capecitabine
Jiangsu HengRui Medicine Co., Ltd.
HER2 Positive Metastatic Breast Cancer
10/16
12/18
M14LTK, NCT02230553: Lapatinib Plus Trametinib in KRAS Mutant NSCLC

Unknown status
1/2
30
Europe
Lapatinib, trametinib
The Netherlands Cancer Institute, GlaxoSmithKline
Colorectal Cancer
08/18
12/19

Download Options